Emcure Pharmaceuticals IPO

Leading Position: Emcure has a long standing market presence and, since they began focusing on Indian domestic branded generics in 1995, they have successfully grown to being the 13th largest pharmaceutical company in India by sales and 4th largest by market share.

Brand Building Capabilities: Company has demonstrated strong capabilities and a proven track record in building brands. Eight of their brands were ranked among the 300 highest selling brands in the IPM. In addition, 17 of the top 20 brands were each ranked among the three highest selling brands in their respective therapeutic areas.

Strong International Presence: Company has a strong track record of successfully entering and growing its presence in new markets through inorganic expansion. Their focus in international markets is on developing products, which are differentiated and require significant expertise, and, as such, are subject to less competition and allows high margins.

Strong R&D Capabilities : Company has five R&D facilities in India, and has established dedicated teams for new product development with 552 qualified scientists. They have strong in-house R&D expertise, which has allowed them to develop a differentiated portfolio products that gives a competitive advantage in the market.

Manufacturing Capability: They have 13 manufacturing facilities across Maharashtra, Gujarat, Sikkim and Karnataka and Jammu and Kashmir, in India. The facilities are capable of producing pharmaceutical products of a wide range of dosage forms.

Quality Control: Pharmaceutical companies are required to comply with the regulations and quality standards stipulated by regulators in India and other jurisdictions. Any failure to comply with applicable quality standards may result in product liability claims and adversely affect our business.

Government Regulations: They are subject to extensive government regulations and if they fail to obtain or renew statutory and regulatory licenses, permits and approvals required to operate, the business and cash flows may be adversely affected.

Working Capital Requirements: They have significant working capital requirements. If company experiences insufficient cash flows to fund working capital, there may be an adverse effect on the business.